Pharming Group to Publish 2025 Results on March 12
Pharming Group N.V. announces that it will present its unaudited preliminary financial results for the fourth quarter and the full year of 2025 on Thursday, March 12, 2026, according to the press release. A conference call and webcast for analysts and investors are scheduled for the same day.
Detailed Announcement and Event Schedule
The Dutch biopharmaceutical group will disclose its preliminary financial results for the fourth quarter and the entire year of 2025 on March 12, 2026, the company states. A conference call and webcast are set for 1:30 PM Central European Time (8:30 AM New York Time) aimed at analysts and investors. Pre-registration is required to participate in the conference call or to follow the live webcast. Pharming notes that only telephone-connected participants will be able to ask questions during the event. The webcast will also be available on the company's website in the investor relations and financial documents section, and a recording will be posted shortly after the event.
Company Profile and Operations
Pharming Group N.V., listed on Euronext Amsterdam and the Nasdaq, identifies itself as a global biopharmaceutical company specializing in the development and marketing of treatments for patients suffering from rare, debilitating, and potentially life-threatening diseases, according to the press release. The group's portfolio of innovative drugs includes small molecules and biological products. The company is headquartered in Leiden, Netherlands, and employs a significant portion of its staff in the United States, the company indicates.
Registration Links and Additional Information
The registration links for the conference call and webcast are available in the press release issued this Thursday, February 26. Investors and analysts may register in advance to receive the connection details and a unique PIN code for accessing the event. For further information, Pharming refers to its website and provides contact details for investor relations and media relations. Michael Levitan, Vice President of Investor Relations and Corporate Communications, is the primary contact for investors. Media relations are handled by Saskia Mehring globally, Ethan Metelenis in the United States, and Leon Melens in the Netherlands.
